Applied DNA Sciences Appoints Cosmetic Industry Veteran Elizabeth M. Schmalz Ferguson to Board of Directors
May 15 2017 - 5:30AM
Business Wire
Applied DNA Sciences, Inc. (Applied DNA, “the Company”) (NASDAQ:
APDN), a provider of DNA-based supply-chain, anti-counterfeiting
and anti-theft technology, product genotyping and DNA mass
production for diagnostics, appointed Elizabeth M. Schmalz Ferguson
to the Company’s Board of Directors, effective June 1, 2017. Ms.
Ferguson was selected to serve based on her sterling track record
of accomplishments as a strategist and product leader within the
cosmetics industry. This appointment brings the total number of
Board members to eight.
Dr. James Hayward, president and CEO of Applied DNA, said, “The
addition of Betsy Schmalz Ferguson to our Board is aligned with our
strategy to expand the application of our technologies within the
cosmetics market, and we expect we will benefit greatly from her
expertise. We welcome her to the Board and look forward to working
together as we increase our presence in the cosmetics and personal
care industries.”
Ms. Ferguson said, “Increasingly, over the course of my career,
consumers have been more vocal in demanding information on the
origin of their personal care and cosmetic products, so they make
empowered choices in the quality of products they use. I am proud
to join the Board of Directors of Applied DNA. I believe the
Company offers a powerful tool for ensuring the authenticity and
identity of ingredients that move through the supply chain and make
it into consumers’ hands, and onto their skin. I believe I can
apply my 30-plus years’ experience to assist in these initiatives
and am enthusiastic about working with the rest of the Applied DNA
team as they strive to bringing authenticated products to
market.”
An innovator in the cosmetics and fragrance industry, Ms.
Ferguson started her senior management career at Revlon with
responsibility for new product development for companies including
Borghese, Ultima II, and Prestige fragrances. Later, as Senior Vice
President of Corporate Product Development at Estée Lauder, her
responsibilities included overseeing product development for some
of the company’s most prominent brands. Subsequently, she was
Executive Vice President of Product Development at Bath and Body
Works and Victoria’s Secret for The Limited. She currently serves
as President of American Flavors & Fragrances, a fragrance
company, and President of her own consulting firm, Betsy Schmalz
Ferguson & Associates. She is an active member of Cosmetic
Executive Women. She earned a bachelor’s degree in psychology from
Georgian Court University.
About Applied DNA Sciences
Applied DNA Sciences makes life real and safe by providing
innovative, molecular-based technology solutions and services that
can help protect products, brands, entire supply chains, and
intellectual property of companies, governments and consumers from
theft, counterfeiting, fraud and diversion. The proprietary
DNA-based “CertainTTM” Platform can be used to identify, tag,
track, and trace products, to help assure authenticity, origin,
traceability and quality of products. SigNature® DNA describes
the core technology ingredient that is at the heart of a family of
uncopyable, security and authentication solutions such as
SigNature® T and fiberTyping®, targeted toward textiles and
apparel, BackTrac™ and DNAnet®, for anti-theft and loss prevention,
and digitalDNA®, providing powerful track- and-trace. All provide a
forensic chain of evidence, and can be used to prosecute
perpetrators. Applied DNA Sciences is also engaged in the
large-scale production of specific DNA sequences using the
polymerase chain reaction.
Go to adnas.com for more information, events and to learn
more about how Applied DNA Sciences makes life real and
safe. Common stock listed on NASDAQ under the symbol APDN, and
warrants are listed under the symbol APDNW.
Forward-Looking Statements
The statements made by APDN in this press release may be
“forward-looking” in nature within the meaning of the Private
Securities Litigation Act of 1995. Forward-looking statements
describe APDN’s future plans, projections, strategies and
expectations, and are based on assumptions and involve a number of
risks and uncertainties, many of which are beyond the control of
APDN. Actual results could differ materially from those projected
due to our short operating history, limited financial resources,
limited market acceptance, market competition and various other
factors detailed from time to time in APDN’s SEC reports and
filings, including our Annual Report on Form 10-K filed on December
6, 2016, and our quarterly reports on Form 10-Q filed on February
9, 2017 and May 11, 2017, which are available at www.sec.gov. APDN
undertakes no obligation to update publicly any forward-looking
statements to reflect new information, events or circumstances
after the date hereof to reflect the occurrence of unanticipated
events, unless otherwise required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170515005444/en/
Investors:Applied DNA Sciences, Inc.Debbie Bailey,
631-240-8817debbie.bailey@adnas.comorMedia:DGI CommSusan
Forman, 212-825-3210sforman@dgicomm.comorProgram:Barbara
BrockwayDirector, Personal
Carebarbara.brockway@adnas.comorwww.adnas.com@APDN
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Apr 2023 to Apr 2024